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Design: Case-control study.
Setting: Not applicable.
Patient(s): In all, 1,550 women with normoandrogenic (n ¼ 686) or hyperandrogenic (n ¼ 842) PCOS and 447 control women were
divided into three age groups: <30, 30–39, and >39 years).
Interventions(s): None.
Main Outcome Measure(s): Body mass index (BMI), waist circumference, blood pressure, glucose, insulin, cholesterol, lipoproteins,
triglycerides and high-sensitivity C-reactive protein.
Result(s): Both normo- and hyperandrogenic womenwith PCOSwere more obese, especially abdominally. They had increased serum levels
of insulin (fasting and in oral glucose tolerance tests), triglycerides, low-density lipoprotein, and total cholesterol, higher blood pressure, and
lower high-density lipoprotein levels independently from BMI compared with the control population as early as from young adulthood until
menopause. The prevalence of metabolic syndrome was two- to ﬁvefold higher in women with PCOS compared with control women,
depending on age and phenotype, and the highest prevalence was observed in hyperandrogenic women with PCOS at late reproductive age.
Conclusion(s): When evaluating metabolic risks in women with PCOS, androgenic status, especially abdominal obesity and age,
should be taken into account, which would allow tailored management of the syndrome from early adulthood on. (Fertil Steril
2017;107:788–95. 2016 by American Society for Reproductive Medicine.)
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Fertility and Sterility®P olycystic ovary syndrome (PCOS) is the most commonendocrine disorder affecting reproductive-age women(incidence 6%–18% depending on the population and
the diagnostic criteria used) (1, 2). It is known to
have multifaceted unfavorable effects on women's health. In
addition to anovulatory infertility, which is typically associated
with the syndrome, women with PCOS exhibit numerous
metabolic risk factors, such as abdominal obesity, insulin
resistance, impaired glucose tolerance, dyslipidemia, and
chronic inﬂammation (3–6). Hyperandrogenism (HA) plays a
central role in the syndrome and has been associated with a
more severe metabolic proﬁle in some, but not all, studies (7–
11). Obesity is common in PCOS and exacerbates the
symptoms and promotes negative health consequences by
increasing the risks of type 2 diabetes (T2DM) and
cardiovascular disease (CVD). However, regarding the
interaction between weight, weight gain, and
hyperandrogenism, the results of earlier studies have been
inconsistent. Some data suggest that the metabolic risks linked
to PCOS are mainly related to obesity and insulin resistance,
whereas others support the hypothesis that the syndrome per
se, especially HA, independently from BMI, are the most
important cardiovascular risks (12–14). According to the
results of some studies, the unfavorable metabolic proﬁle
linked to PCOS seems to worsen after the menopausal
transition, highlighting the lifelong health burden of the
syndrome (3, 15). A recent study, however, could not conﬁrm
any association between a history of androgen excess and
menstrual irregularity with worsening of metabolic health after
menopause (16).
In women without PCOS, an impaired metabolic proﬁle is
associated with obesity and weight gain. Especially during the
menopausal transition, weight gain has been shown to have
an adverse effect on glucose metabolism (17). Furthermore,
circulating levels of ovarian and adrenal androgens do not
seem to have a signiﬁcant impact on chronic inﬂammation
markers or lipid proﬁle in women in the general population,
whereas a low serum level of SHBG is an independent predic-
tor of an increased risk of CVD (18, 19).
Given the lack of data regarding age-related metabolic
changes in women with PCOS, the aim of the present study
was to explore and compare metabolic proﬁles in women
with PCOS and in control women throughout their reproduc-
tive life spans in a cross-sectional dataset. We also aimed to
identify speciﬁc metabolic risk factors and the impact of hy-
perandrogenism in PCOS during early adulthood.MATERIALS AND METHODS
Study Population
Women taking part in eight Nordic PCOS studies contributed to
the present investigation. Two centers in Finland, three in Swe-
den, two in Norway, and one in Denmark were involved, and
there were totals of 1,550 women with PCOS (age range 14–
59 years) and 447 control women without the syndrome (age
range 18–62 years) (6,20–27). The women with PCOS were
recruited both from hospital gynecology or infertility clinics
and from the community with advertisements in local
newspapers and the healthy control women from theVOL. 107 NO. 3 / MARCH 2017community by advertisements in local newspapers. Circulating
levels of androgens in a subpopulation of this Nordic PCOS
cohort population have been recently published (28).
Diagnoses of PCOS were made according to the Rotterdam
criteria (29). Diagnosis of PCOS in peri- and postmenopausal
women was based on the presence of oligo-amenorrhea com-
bined with hyperandrogenism (either biochemical or clinical)
reported at reproductive age. Thus, retrospectively, all of the
women met the Rotterdam criteria. Ovarian morphology was
examined by means of transvaginal ultrasonography in all
participants. Biochemical hyperandrogenism was deﬁned in
relation to the upper limits used in the respective laboratories,
depending on themethod used, and clinical hyperandrogenism
was diagnosedwhen a subject had a Ferriman-Gallwey score of
>7. The Ferriman-Gallwey scoring was performed by a physi-
cian in all studies. The PCOS population was further divided
into two groups: hyperandrogenic women with PCOS (HA-
PCOS, including biochemical and/or clinical hyperandrogen-
ism) and normoandrogenic women with PCOS (NA-PCOS,
including women with both oligo-amenorrhea and polycystic
ovaries observed in ultrasonography). The control population
consisted of women with normal ovaries (according to ultraso-
nography) and absence of PCOS-related symptoms, e.g., oligo-
or anovulation and/or hirsutism and/or elevated serum T
levels. The PCOS and control groups were grouped according
to age as follows: <30 years, 30–39 years, and >39 years.
Women using hormonal preparations, medication affecting
androgen levels and glucose metabolism, as well as statins or
antihypertensive drugs were excluded from the study. Alterna-
tively, a 2-month washout period for hormonal preparations or
medication affecting androgen levels was required before
entering the study. Furthermore, none of the women had
T2DM, because having the diagnosis of preexisting diabetes
was an exclusion criterion in all studies.
BMI was calculated as kg/m2. Waist circumference was
assessed according to a generally accepted method. Both sys-
tolic and diastolic blood pressures (BPs) were measured in a
sitting position after 15 minutes of resting.
A diagnosis of metabolic syndrome (MetS) was made ac-
cording to the Rotterdam consensus (28), requiring three out
of the following ﬁve criteria: waist circumference >88 cm
and/or BMI R30 kg/m2, triglycerides R150 mg/dL
(1.70 mmol/L), high-density lipoprotein (HDL) %50 mg/dL
(1.30 mmol/L), systolic BP R130 mm Hg and/or diastolic
BP R85 mm Hg, and fasting glucose R110–126 mg/dL
(6.11–6.99 nmol/L) and/or 2-hour oral glucose tolerance
test (OGTT) glucoseR140–199 mg/dL (7.78–11.04 nmol/L).Laboratory Methods
Themetabolic variables (glucose, insulin, cholesterol, lipopro-
teins, triglycerides, and high-sensitivity C-reactive protein)
were assayed by means of the routine methods used in the
laboratories of the different study centers (6,19–26).
According to the Nordic Reference Interval Project 2000
(30) the reference ranges for the serum lipid levels were
similar in all subpopulations of the study.
In ﬁve study populations (20–25), assays of T were
performed by means of liquid chromatography–mass789
TABLE 1
Anthropometric and metabolic parameters in the polycystic ovary syndrome and control women.
Metabolic parameter
Control PCOS
P valuen Result n Result
Age (y) 447 33.5 (9.9) 1,550 30.0 (7.2) < .001
BMI (kg/m2) 447 25.9 (5.4) 1,497 29.2 (6.9) < .001
Waist (cm) 312 87.6 (14.6) 1,204 92.9 (17.5) < .001
Testosterone (nmol/L) 433 1.1 (0.5) 1,359 1.8 (1.0) < .001a
Fasting glucose (mmol/L) 376 5.1 (0.9) 1,104 5.1 (0.6) NS
Fasting insulin (mU/L) 372 7.4 (6.0) 1,093 12.3 (11.1) < .001a
Total cholesterol (mmol/L) 364 4.6 (0.9) 982 4.8 (1.0) .003a
HDL (mmol/L) 346 1.5 (0.3) 960 1.4 (0.4) < .001a
LDL (mmol/L) 347 2.6 (0.8) 863 2.9 (0.9) < .001a
Triglycerides (mmol/L) 366 0.9 (0.5) 974 1.3 (0.8) < .001a
OGTT glucose, 2 h (mmol/L) 140 5.0 (1.3) 681 5.8 (1.8) < .001
OGTT mean glucose (mmol/L) 140 5.0 (0.8) 681 5.5 (1.1) < .001
OGTT insulin, 2 h (mU/L) 152 27.4 (20.5) 860 71.7 (73.9) < .001a
OGTT mean insulin (mU/L) 152 17.2 (12.0) 840 42.6 (41.6) < .001a
Systolic BP (mm Hg) 318 118.2 (15.6) 1,276 123.43 (16.2) < .001a
Diastolic BP (mm Hg) 318 74.3 (12.1) 1,276 78.5 (12.1) < .001a
hs-CRP (mg/L) 159 1.5 (3.0) 761 2.8 (3.8) < .001
Note: Data presented as n or mean (SD), unless stated otherwise. BMI¼ body mass index; BP¼ blood pressure; HDL¼ high-density lipoprotein; hs-CRP¼ high-sensitivity C-reactive protein; LDL¼
low-density lipoprotein; OGTT ¼ oral glucose tolerance test.
a Statistical signiﬁcance (P< .05) remains after adjustment for age and BMI.
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chemiluminometric immunoassay at NordLab Oulu, as
reported earlier (28). In the remaining three study sites (not
included in our previous publication), T was analyzed with
the use of radioimmunoassay (26, 27). To deﬁne biochemical
hyperandrogenism age, method- and laboratory-speciﬁc refer-
ence ranges were used in the different subgroups. All of the an-
alyses were also performed in a subpopulation including only
the women with T measured with the use of LC/MS.
The mean OGTT plasma glucose level and mean OGTT
serum insulin levels were calculated as the means of concen-
trations at different time points ([basal þ 2-hour]/2).
Conversion factors ([SI unit]/[conversion factor]¼metric
unit) to metric units for the laboratory parameters were as fol-
lows: glucose 0.056 (mg/dL), triglycerides 0.011 (mg/dL), and
total cholesterol, HDL, and low-density lipoprotein (LDL)
0.026 (mg/dL).Statistical Methods
Comparisons of continuous variables were carried out with
the use of Student t test or the (nonparametric) Mann-
Whitney U test, depending on the distribution of the variable.
One-way analysis of variance was used in multiple group an-
alyses with Scheffe and Tukey post hoc analyses. Adjustments
for BMI and age were applied with the use of linear regression
analysis. For categoric variables, the c2-test was used. Statis-
tical analyses were performed with the use of SPSS 21.0 and
22.0 software. Of note, the number of participants varied be-
tween analyses owing to the lack of measurements in some
cases.
Informed consents were obtained from all women at the
original study sites, and the study was approved by the Ethics
Committees of the respective study sites.790RESULTS
The women with PCOS (n¼ 1,550) had higher BMIs and waist
circumferences than the control population (n ¼ 447). They
also presented with signiﬁcantly lower levels of HDL and
higher levels of insulin (fasting and during OGTTs), total
cholesterol, LDL, triglycerides, and BP (both systolic and
diastolic) compared with the control women after adjusting
for BMI (Table 1).
The anthropometric and metabolic parameters in the
HA-PCOS group (n ¼ 842), the NA-PCOS group (n ¼ 684),
and the control women (n ¼ 447) are presented in Table 2
and Figures 1 and 2. Only the results that remained
signiﬁcant after adjustment for BMI and age are presented
in the text.Comparisons Between the HA-PCOS, NA-PCOS,
and Control Groups
BMI and waist circumference. BMIs and waist circumfer-
ences were signiﬁcantly greater in both the HA- and the
NA-PCOS subpopulations compared with the control group.
In addition, BMI was greater in the HA-PCOS women
compared with the NA-PCOS women (Table 2).
In age-group analyses, women in the HA-PCOS and NA-
PCOS groups had greater BMIs and waist circumferences in all
age groups compared with the control group. In the age
groups of 30–39 years and >39 years, the women in the
HA-PCOS group had higher BMIs and waist circumferences
than the women in the NA-PCOS group (Fig. 1).
Glucose tolerance and insulin resistance. Women in the
HA-PCOS and NA-PCOS groups were more hyperinsulinemic
(higher fasting and OGTT insulin levels) than the control
women, and women in the NA-PCOS group were less glucoseVOL. 107 NO. 3 / MARCH 2017
TABLE 2
Anthropometric and metabolic parameters in the study populations.
Metabolic parameter
Control NA-PCOS HA-PCOS
P valuea P valueb P valuecn Result n Result n Result
Age (y) 447 33.5 (9.9) 684 29.9 (7.0) 842 30.0 (7.4) < .001 < .001 NS
BMI (kg/m2) 447 25.9 (5.4) 666 28.8 (7.0) 811 29.4 (6.7) < .001 < .001 .027
Waist (cm) 312 87.6 (14.6) 590 92.1 (17.8) 604 93.6 (17.0) < .001 < .001 NSd
Testosterone (nmol/L) 433 1.1 (0.5) 617 1.4 (0.5) 742 2.1 (1.1) < .001d < .001d < .001d
Fasting glucose (mmol/L) 376 5.1 (0.9) 542 5.1 (0.6) 552 5.1 (0.6) NS NS NS
Fasting insulin (mU/L) 372 7.4 (6.0) 544 12.0 (11.4) 537 12.4 (10.7) < .001d < .001d NS
Total cholesterol (mmol/L) 364 4.6 (0.9) 368 4.7 (0.9) 603 4.8 (1.0) .041 .004d NS
HDL (mmol/L) 346 1.5 (0.3) 364 1.3 (0.5) 586 1.4 (0.4) < .001d < .001d .013
LDL (mmol/L) 347 2.6 (0.8) 349 2.8 (0.8) 504 2.9 (0.9) < .001d < .001d NS
Triglycerides (mmol/L) 366 0.9 (0.5) 367 1.2 (0.7) 596 1.2 (0.8) < .001d < .001d NS
OGTT glucose, 2 h (mmol/L) 140 5.0 (1.3) 442 5.9 (1.7) 238 6.0 (1.9) < .001d < .001 NS
OGTT mean glucose (mmol/L) 140 5.0 (0.8) 442 5.4 (1.0) 238 5.5 (1.1) < .001 < .001 NS
OGTT insulin, 2 h (mU/L) 152 27.4 (20.5) 476 67.8 (69.4) 376 76.0 (79.0) < .001d < .001d NS
OGTT mean insulin (mU/L) 152 17.2 (12.0) 465 40.9 (40.1) 367 44.5 (43.3) < .001d < .001d NS
Systolic BP (mm Hg) 318 118 (16) 605 123 (16) 657 124 (17) < .001d < .001d NS
Diastolic BP (mm Hg) 318 74 (12) 605 78 (12) 657 79 (12) < .001d < .001d NS
hs-CRP (mg/L) 159 1.5 (3.0) 468 2.8 (3.6) 291 2.9 (4.0) < .001 < .001 NS
Note: Data presented as n or mean (SD), unless stated otherwise. HA ¼ hyperandrogenic; NA ¼ normoandrogenic; NS ¼ not signiﬁcant; other abbreviations as in Table 1.
a P value between reference group and NA-PCOS.
b P value between reference group and HA-PCOS.
c P value between NA- and HA-PCOS groups.
d Statistically signiﬁcant (P< .05) after adjustment for age and BMI.
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Fertility and Sterility®tolerant (higher 2-hour OGTT glucose levels) than the control
women (Table 2).
In the age-group analyses, 2-hour glucose and mean
glucose levels in OGTTs were higher in the HA-PCOS and
NA-PCOS groups than in the control women in the age group
of 30–39 years (P¼ .001 and P¼ .024, respectively). Two-hour
insulin and mean OGTT insulin levels were signiﬁcantly
higher in the women of ageR30 years in both PCOS groups
compared with the control group (P¼ .002 and P¼ .008,
respectively). Fasting insulin levels were higher in women
of ages <30 and 30–39 years in the NA-PCOS group
(P¼ .041 and P¼ .021, respectively) and in women of age
>39 years in the HA-PCOS group (P¼ .003) compared with
the level in the control women (Fig. 1).
Lipids. Serum total cholesterol levels were higher in the HA-
PCOS group than in the control group. Serum levels of HDL
were lower and those of triglycerides and LDL higher in
both PCOS populations compared with the control women
(Table 2).
In the age group analyses, in women<30 years of age in
both the NA- and HA-PCOS groups had worse lipid proﬁles
compared with the control population. Women >39 years
of age in the HA-PCOS group presented with higher levels
of LDL and triglycerides compared with controls and higher
levels of LDL compared with the NA-PCOS population
(Fig. 2).High-Sensitivity C-Reactive Protein
There were no signiﬁcant differences between study groups in
serum levels of high-sensitivity C-reactive protein in any of
the age groups after adjustment for BMI.VOL. 107 NO. 3 / MARCH 2017Blood Pressure
Both systolic and diastolic BPs were signiﬁcantly increased in
both PCOS populations compared with control women
(Table 2).
Age group analyses revealed that systolic BP was signif-
icantly higher in all age groups of the NA-PCOS group and in
women R30 years of age in the HA-PCOS group compared
with the control group (Fig. 2). Diastolic BP was higher in
all age groups of the HA-PCOS group and in women
<40 years of age in the NA-PCOS group compared with con-
trol women (data not presented).Prevalence of Metabolic Syndrome
In women<30 years of age the prevalence of MetS was ﬁve-
fold higher and in women<40 years of age twofold higher in
both PCOS populations compared with the control women.
However, in women>39 years of age, the difference between
the NA-PCOS and control groups had disappeared, whereas
the prevalence of MetS remained twofold higher in the
HA-PCOS group compared with the NA-PCOS or control
groups (Supplemental Table 1, available online at
www.fertstert.org).
In age-group analyses, isolated parameters of the meta-
bolic risk proﬁle did not considerably differ between PCOS
subpopulations, except for alterations of glucose metabolism
and HDL in the age group of 30–39 years, and higher BMIs
and waist circumferences in the age group of >39 years in
the HA-PCOS compared with the NA-PCOS group. These re-
sults were identical when using International Diabetes Feder-
ation criteria for MetS.791
FIGURE 1
Body mass indices, waist circumferences, and parameters of glucose metabolism at different ages in the study populations. The bars represent
means and the error bars standard deviations. Results are adjusted for body mass index. PCOS ¼ polycystic ovary syndrome.
Pinola. Metabolic proﬁle in women with PCOS. Fertil Steril 2016.
ORIGINAL ARTICLE: REPRODUCTIVE ENDOCRINOLOGYAnalyses in the Subpopulation of Women With
Testosterone Measured by Means of LC/MS
All the results were similar except for the differences in serum
lipid concentrations between the groups, which became
nonsigniﬁcant, most probably because of the decreased po-
wer for the analysis in this subpopulation (data not
presented).DISCUSSION
In this largeNordicmulticenter collaboration study,wedemon-
strated that women with PCOS already had an unfavorable
metabolic proﬁle in early adulthood, lasting until menopause.
Furthermore, we found no signiﬁcant differences in individual
metabolic parameters between the NA-PCOS and HA-PCOS
groups after adjustment for BMI, strongly suggesting a predom-
inant role of obesity, speciﬁcally abdominal obesity, in the
severity of the syndrome. Nevertheless, the prevalence of
MetSwas twofold higher in theHA-PCOSpopulation compared
with the NA-PCOS and control groups during late reproductive
years, suggesting that hyperandrogenism also is implicated, at
least in the long term, in the adverse metabolic proﬁle seen in
PCOS.
The present data indicate that both NA- and HA-PCOS
group women were more obese (especially abdominally), hy-
perinsulinemic, and dyslipidemic and exhibited higher BP792levels throughout their life spans compared with the control
population. More speciﬁcally, even after adjusting for BMI,
the women in the NA-PCOS group were more glucose intol-
erant, insulin resistant, hyperinsulinemic, and dyslipidemic,
especially in early adulthood, compared with the control
women, which is in line with earlier data indicating that the
differences between normoandrogenic women with PCOS
and healthy women, as well as the adverse metabolic out-
comes in PCOS, are mainly related to abdominal obesity
(31, 32). In some studies, however, oligo-amenorrheic nor-
moandrogenic women with PCOS exhibited a more favorable
metabolic phenotype compared with their hyperandrogenic
counterparts (7), and other studies have highlighted the role
of hyperandrogenism as a cardiovascular risk factor in
women with PCOS (5, 33).
Of note, both groups of women with PCOS (HA- and NA-
PCOS) exhibited already in early adulthood an adverse lipid
proﬁle which, together with BMI, waist circumference, and
BP, seemed to worsen with age in both PCOS groups and in
control women, supporting the results of earlier studies (5,
26). As for glucose metabolism, only women with PCOS
aged 30–39 years exhibited higher glucose and insulin
levels in OGTTs compared with control women. The results
of follow-up studies up to the postmenopausal period (15,
34) are in line with our data, showing adverse changes in
metabolic proﬁle and BP at early ages in women with PCOSVOL. 107 NO. 3 / MARCH 2017
FIGURE 2
Lipids at different ages in the study populations. The bars represent the means and the error bars the standard deviations. Results are adjusted for
body mass index. PCOS ¼ polycystic ovary syndrome.
Pinola. Metabolic proﬁle in women with PCOS. Fertil Steril 2016.
Fertility and Sterility®independently from obesity. In particular, a high level of
triglycerides has been shown to be an independent predictor
of future risk of myocardial infarction, and low levels of
HDL reﬂect cardiovascular morbidity (35) and are associated
with elevated cardiovascular risks in general, especially in
women (36). Moreover, the difference in BP (4–5 mm Hg
between the PCOS and control groups), though relatively
modest, has clinical signiﬁcance, because it was already
present in women <30 years of age and continuing
thereafter. It has been estimated that an increase of BP of
only 1.5–2 mm Hg could have a large impact on CVD risk
at population level, and reduction of mildly and/or
moderately elevated BP to normal levels has been
associated with a reduced risk of CVD in a large placebo-
controlled study (37). The present observations ﬁt with recent
epidemiologic data indicating that women with PCOS have
increased risk factors of ischemic heart and cerebrovascular
diseases, independently from obesity (38). However, in
women without PCOS, an impaired metabolic proﬁle has
been associated with obesity and weight gain, especially dur-
ing the period of menopausal transition (17), and this also
seems to be the case in PCOS. All in all, the results highlight
the importance of screening for PCOS and overweight/obesity
in early adulthood to tailor treatment and intervention proto-
cols and reduce the risks of future CVD and T2DM.
The prevalence of MetS was signiﬁcantly higher in
women with PCOS (31.5%) throughout their reproductiveVOL. 107 NO. 3 / MARCH 2017life spans compared with control women, who exhibited a
MetS prevalence of 12%, as also observed in general Nordic
populations (39–41). The prevalence was not increased in
women with NA-PCOS compared with control women in
the age group >39 years, which may be a result of the rela-
tively low number of women and similar waist circumfer-
ences in this age group. Again, this ﬁnding supports the
postulation that abdominal obesity is the principal determi-
nant of metabolic abnormalities in PCOS (32), but it is also
consistent with earlier observations linking hyperandrogen-
ism to metabolic disturbances and a higher prevalence of
MetS (11). Even though isolated parameters of the metabolic
risk proﬁle did not considerably differ between the NA- and
HA-PCOS populations, lifelong exposure to hyperandrogen-
ism may end up being an additional risk factor of MetS later
in life. In keeping with this, in our study population, serum
levels of LDL were slightly higher in women in the HA-
PCOS group compared with the NA-PCOS group in women
aged R40 years. Hyperandrogenism may directly or indi-
rectly inﬂuence metabolic abnormalities and contribute to
abdominal obesity. However, controversial data has been
published recently indicating that a history of hyperandro-
genism is not always associated with metabolic disturbances
after menopause (16). More research is needed to provide a
better understanding of the interaction between hyperandro-
genism, insulin resistance, and abdominal adiposity in
PCOS (32).793
ORIGINAL ARTICLE: REPRODUCTIVE ENDOCRINOLOGYThe strengths of the present study are the inclusion of a
large number of cases of HA- and NA-PCOS from a young
fertile age to menopause. Moreover, the study population
was remarkably homogeneous regarding ethnicity, with all
the women being ‘‘white.’’ This is of great importance,
because the phenotypic and metabolic proﬁles of women
with PCOS show a high degree of ethnic variation (8, 38).
The PCOS cohorts were recruited from eight different study
sites, but in all cases the diagnoses of PCOS were made
with the use of the Rotterdam criteria. The present results
underscore the role of abdominal obesity and, to a lesser
degree, hyperandrogenism in the development of lifelong
metabolic risks in Nordic women with PCOS, and most
probably women in other populations as well. One
limitation is the cross-sectional study design, which can
cause bias due to heterogeneity in the characteristics of the
participants in the different age groups. Furthermore, the
control group was smaller than the PCOS group, because
not all of the trials contributing to this collaborative study
included a control population. The women with T2DM and
those using statins or antihypertensive drugs had been
excluded from the study populations, which may have
decreased the differences between control and PCOS women.
The methods for laboratory analyses varied between subpop-
ulations in different study sites, but all were carried out ac-
cording to accredited methods, and speciﬁc reference
ranges of the laboratory were used in the deﬁnition of
biochemical hyperandrogenism. It has to be noted that
52% of the T and 50% of the SHBG measurements were per-
formed at only one study site (28). The upper limit for T in
deﬁning biochemical hyperandrogenism did not take into
account the physiologic decline in serum levels observed
with age. Therefore, some hyperandrogenic women
>39 years of age may have been classiﬁed as normoandro-
genic, which could narrow the differences between the HA-
and NA-PCOS groups. Finally, we could not separate the par-
ticipants into pre- and postmenopausal groups to study more
speciﬁcally the effect of menopausal transition on metabolic
indices, because there were too few women older than
50 years to obtain reliable results in age group comparisons.CONCLUSION
This Nordic multicenter study showed that women with PCOS
presented a worsened metabolic proﬁle compared with a con-
trol population from early adulthood to menopause. Even
though lifelong exposure to hyperandrogenemia seemed to
contribute, at least in part, to a higher prevalence of MetS,
metabolic disturbances were present in both the HA- and the
NA-PCOS groups, and abdominal obesity appeared to be the
principal determinant of metabolic abnormalities in PCOS.
We conclude that when evaluating metabolic risks in
women with PCOS, androgenic status, obesity (especially
abdominal obesity), and age should all be taken into account
to allow tailored management of the syndrome, focusing on
prevention of abdominal obesity, starting from early adult-
hood. However, only a long-term, longitudinal follow-up
study will reveal whether the metabolic risk factors linked794to PCOS, and more speciﬁcally to HA, translate into later car-
diovascular morbidity and mortality.
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SUPPLEMENTAL TABLE 1
Prevalence of the metabolic syndrome (MetS) and its components in differe dam criteria for metabolic syndromea.
MetS component
<30 y >39 y
Control NA-PCOS HA-PCOS
Met-S 7 (5.1)b,c 62 (26.3)b 64 (26.7
Waist or BMIa 41 (33.6)b,c 172 (53.6)b 159 (50.3
TGa 5 (2.9)b,c 33 (19.0)b 54 (17.6
HDLa 35 (21.9)b,c 89 (51.1)b 138 (45.2
BPa 21 (15.9)b,c 111 (33.5)b 131 (38.0
Glucosea 4 (8.0) 33 (13.3) 22 (17.2
Note: Data presented as n (%). BMI ¼ body mass index; BP ¼ blood pressure; HA ¼ hyperandrogenic
a Rotterdam criteria for metabolic syndrome (MBS), three out of ﬁve: waist circumference >88 cm and
R7.78 nmol/L.
b Statistically signiﬁcant difference between reference and NA-PCOS groups.
c Statistically signiﬁcant difference between reference and HA-PCOS groups.
d Statistically signiﬁcant difference between NA-PCOS and HA-PCOS groups.
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30–39 yControl NA-PCOS HA-PCOS Control NA-PCOS HA-PCOS
)c 16 (18.0)b,c 57 (37.5)b 68 (40.0)c 12 (18.2)c 8 (19.5)d 14 (42.4)c,d
)c 57 (50.0)b,c 147 (65.6)b 171 (69.8)c 35 (46.1)c 18 (41.9)d 31 (73.8)c,d
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) 5 (15.2) 27 (16.6)d 27 (27.6)d 15 (21.1) 7 (18.9) 11 (34.4)
; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; NA ¼ normoandrogenic; PCOS ¼ polycystic ovary syndrome; TG ¼ triglycerides.
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SUPPLEMENTAL TABLE 2
Sources of the subpopulations in the study.
Population
PCOS population Control population
n Source Age (y), range (mean) n Source Age (y), range (mean)
Population 1a 319 Clinic 19–39 (28.2) – – –
Population 2b,c,d 104 Clinic 18–59 (37.9) 124 Community 19–62 (33.2)
Population 3e 118 Community/clinic 18–38 (29.8) 52 Community/clinic 18–39 (28.6)
Population 4f 91 Community/clinic 18–41 (28.6) – – –
Population 5g 70 Community/clinic 18–58 (42.0) 75 Community/clinic 33–59 (43.2)
Population 6h 488 Community/clinic 15–50 (29.4) 116 Community/clinic 20–54 (30.9)
Population 7i 43 Community/clinic 21–39 (30.8) – – –
Population 8j 317 Community/clinic 14–45 (27.8) 80 Community/clinic 19–51 (32.0)
a Morin-Papunen et al. 2000.
b Puurunen et al. 2009.
c Piltonen et al. 2004.
d Piltonen et al. 2012.
e Stener-Victorin et al. 2010.
f Vanky et al. 2003.
g Hudecova et al. 2009.
h Glintborg et al. 2012.
i Nybacka et al. 2011.
j Unpublished.
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